Alvotech signs licensing deal with Lotus Pharmaceutical for two biosimilars

On August 21, 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical covering two of its biosimilar candidates. The deal involves AVT34, a proposed biosimilar to Imfinzi (durvalumab), and AVT87, a proposed biosimilar to Hemlibra (emicizumab), for the U.S. market and selected Asian markets.¹

For context on the reference products, Imfinzi is an oncology biologic used across multiple cancer types that brought in roughly $6.1 billion in global sales in 2025.¹ Hemlibra, used for routine prophylaxis in hemophilia A patients, generated approximately CHF4.8 billion (about $5.8 billion) in global sales in 2025.¹

Under the terms disclosed, the U.S. arrangement is semi-exclusive, with Alvotech keeping the right to commercialize both products itself alongside Lotus, while Lotus will sell them through its U.S. subsidiary Alvogen.¹ Alvotech's role extends beyond commercialization: the company will continue to handle product development and regulatory filings in the U.S., and it will act as the sole manufacturer supplying the products to all markets under the deal.¹

For Asia, Lotus was granted sole commercial rights across eight markets, namely South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong, and Malaysia.¹ In those territories, Lotus will handle regulatory filings and sales locally.¹

On the financial terms, Alvotech could receive up to roughly $150 million total from upfront payments and milestones, separate from the revenue it expects to earn by supplying commercial product.¹

Alvotech CEO Lisa Graver said the agreement marks an important shift in the company's commercial approach, giving it a direct role in U.S. commercialization for the first time and letting it capture more value from its development and manufacturing work.¹ Lotus CEO Petar Vazharov said the partnership meaningfully supports Lotus's global growth strategy.¹